Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
110
datasets available to search
ShareScore release 0.9.0
Dataset results
110 results for “Bisphosphonates”
Bone metabolism gene variation and response to bisphosphonate treatment in women with postmenopausal osteoporosis
<p>This repository contains the raw and source data for the manuscript "Bone metabolism gene polymorphism and response to bisphosphonate treatment in women with postmenopausal osteoporosis" submitted to PLOS ONE.</p> <p><strong>Abstract: </strong></p> <p><em>Introduction:</em> Long-term treatment is used in patients with osteoporosis, and bisphosphonates (BPs) are the most commonly prescribed medications. However, in some patients this therapy is not effective, cause different side effects and complications. Unfortunately, at least one year is needed to identify and confirm an ineffectiveness of BPs therapy on bone mineral density (BMD). Among other factors, a response to BPs therapy may also be explained by genetic factors. The aim of this study was to analyze the influence of <em>SOST, PTH, FGF2, FDPS, GGPS1, </em>and<em> LRP5</em> gene polymorphisms on the response to treatment with BPs.</p> <p><em>Materials and methods: </em>Women with postmenopausal osteoporosis were included to this study if they used bisphosphonates for at least 12 months. Exclusion criteria were: persistence on BPs therapy less than 80%, bone metabolic diseases, diseases deemed to affect bone metabolism, malignant tumours, using of any medications influencing BMD. The study protocol was approved by the local ethics committee. The BMD at the lumbar spine and femoral neck were measured using dual x-ray absorptiometry (GE Lunar) before and at least 12 months after treatment with BPs. According to BMD change, patients were divided in two groups – responders and non-responders to BPs terapy. Polymorphic variants in <em>SOST, PTH, FGF2, FDPS, GGPS1, </em>and<em> LRP5</em> genes were determined using PCR analysis with TaqMan probes (Thermo Scientific).</p> <p><em>Results:</em> In total, 201 women with BPs therapy were included in the study. No statistically significant differences were observed in age, age at menopause, weight, height, BMI and baseline BMD levels between responders (122 subjects) and non-responders (79 subjects).</p> <p>As single markers, the <em>SOST </em>rs1234612 T/T (OR=2.3; P=0.02), <em>PTH</em> rs7125774 T/T (OR=2.8, P=0.0009), <em>FDPS</em> rs2297480 G/G (OR=29.3, P=2.2×10<sup>-7</sup>), and <em>GGPS1</em> rs10925503 C/C+C/T (OR=2.9; P=0.003) gene variants were over-represented in non-responders group. No significant association between <em>FGF2</em> rs6854081 and <em>LRP5</em> rs3736228 gene variants and response to BPs treatment was observed. The carriers of T-T-G-C allelic combination (constructed from rs1234612, rs7125774, rs2297480, and rs10925503) were predisposed to negative response to BPs treatment (OR = 4.9, 95% CI 1.7–14.6, P=0.005). The C-C-T-C combination was significantly over-represented in responders (OR = 0.1, 95% CI 0.1–0.5, P=0.006).</p> <p><em>Conclusions:</em> Our findings highlight the importance of identified single gene variants and their allelic combinations for pharmacogenetics of BPs therapy of osteoporosis. Complex screening of these genetic markers could be used as a new strategy for personalized antiresorptive therapy.</p>
Bisphosphonates for Prevention of Post-Denosumab Bone Loss
ClinicalTrials.gov study NCT03396315. IPD Sharing: UNDECIDED. Countries: 1. Publications: 22.
Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture
ClinicalTrials.gov study NCT01950169. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
ClinicalTrials.gov study NCT00485953. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
ClinicalTrials.gov study NCT00083382. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
ClinicalTrials.gov study NCT01750086. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Nitrates and Bone Turnover; Nitrates and Bone Turnover Bisphosphonate Sub-Study
ClinicalTrials.gov study NCT01387672. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Data from: Oral bisphosphonates are associated with increased risk of atypical femoral fractures in elderly women
Objectives: To evaluate the association between bisphosphonate use and the risk of atypical femoral fractures among women aged 65 or older. Design: Nested case–control study. Setting: General practice research database in Spain. Exposures Use of oral bisphosphonates before the occurrence of atypical fractures among cases or the corresponding index date among controls. Bisphosphonate use was categorised as ever versus never users. Ever users were divided according to the total time since first prescription. Main outcome measures: Cases were defined as women aged 65 years or older with a first diagnosis of subtrochanteric or diaphyseal fracture, recorded in the BIFAP database between 1 January 2005 and 31 December 2008, and with at least 1 year of follow-up before the index date. For each case, five age-matched and calendar-year-matched controls without a history of hip or atypical fracture were randomly selected from the database. Statistical analysis: OR of atypical femoral fracture by bisphosphonate use was determined using conditional logistic regression. Models were adjusted for comorbidities and use of other medications. Results: The analysis included 44 cases and 220 matched controls (mean age, 82 years). Ever use of bisphosphonates was more frequent in cases than controls (29.6% vs 10.5%). In multivariate analyses, OR (95% CI) of atypical femoral fracture was 4.30 (1.55 to 11.9) in ever versus never users of bisphosphonates. The risk increased with long-term use, with an OR of 9.46 (2.17 to 41.3) comparing those using bisphosphonates over 3 years versus no users (p for trend=0.01). Conclusions: Bisphosphonate use was associated with an increased risk of subtrochanteric or diaphyseal fractures in elderly women in a low fracture risk population, with a higher risk among long-term bisphosphonate users.
Supplementary figures to Effect of bisphosphonates on vertebral fractures in HIV infected males: 7-years longitudinal study
<p>Supplementary figures to Effect of bisphosphonates on vertebral fractures in HIV infected males: 7-years longitudinal study</p>
S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
ClinicalTrials.gov study NCT00127205. IPD Sharing: Not stated. Countries: 0. Publications: 2.
MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)
ClinicalTrials.gov study NCT00996801. IPD Sharing: Not stated. Countries: 0. Publications: 2.
A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)
ClinicalTrials.gov study NCT00885170. IPD Sharing: YES. Countries: 0. Publications: 1.
Osteoporosis Choice Decision Aid for Use of Bisphosphonates in Postmenopausal Women
ClinicalTrials.gov study NCT00578981. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Study of Oral Bisphosphonate for Osteopenic Women Treated With Adjuvant Aromatase Inhibitors
ClinicalTrials.gov study NCT02616744. IPD Sharing: NO. Countries: 1. Publications: 2.
Bisphosphonate Prior to Parathyroidectomy in Primary Hyperparathyroidism
ClinicalTrials.gov study NCT06859580. IPD Sharing: YES. Countries: 1. Publications: 45.
Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis
ClinicalTrials.gov study NCT01465568. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effects of Bisphosphonates on OI-Related Hearing Loss
ClinicalTrials.gov study NCT04152551. IPD Sharing: NO. Countries: 1. Publications: 14.
Bisphosphonates Effects On Alveolar Bone Among Osteoporotic Women
ClinicalTrials.gov study NCT02115490. IPD Sharing: Not stated. Countries: 1. Publications: 9.
Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy
ClinicalTrials.gov study NCT02155595. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial
ClinicalTrials.gov study NCT02181101. IPD Sharing: Not stated. Countries: 1. Publications: 6.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.